Graham J. Riley - Concepedia

Author

Graham J. Riley

Also Known As

G Riley, G. J. RILEY, G. J. Riley, G. RILEY, G. Riley, G.J. Riley, GRAHAM J. RILEY, Graham J Riley, Graham J. P. Riley, Graham J. Riley

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Molecular Discovery (United Kingdom)New Frontier GlaxoSmithKline (United Kingdom)

About

Graham J. Riley is an author at Molecular Discovery (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	46	3.1K
2	Natural Sciences	15	17	1.1K
3	Social Sciences	6	6	559
4	Health Sciences	1	1	21
5	Humanities	1	1	43

Graham J. Riley

Publications

5.4K

Citations

H-Index

Page 1

	Year	Citations
SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist G.A. Kennett, Martyn Wood, Fiona Bright, Neuropharmacology Sb 242084Molecular PharmacologyFunctional SelectivityMedicineReceptor Antagonist	1997	523
Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin Andrew D. Medhurst, Carol A. Jennings, Melanie J. Robbins, Journal of Neurochemistry	2003	433
Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A C. Reavill, Stephen G. Taylor, Martyn Wood, Journal of Pharmacology and Experimental Therapeutics	2000	288
Characterization of SB‐269970‐A, a selective 5‐HT<sub>7</sub> receptor antagonist Jim J. Hagan, Gary Price, Nigel Deeks, British Journal of Pharmacology	2000	281
A Novel, Potent, and Selective 5-HT<sub>7</sub>Antagonist: (<i>R</i>)-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970) Peter J. Lovell, Steven M. Bromidge, Steven Dabbs, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceTranslational PharmacologyBiochemistry	2000	248
SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models Warren D. Hirst, Tania O. Stean, Derek C. Rogers, European Journal of Pharmacology Cognitive ScienceNeuropsychologyCognitive NeuroscienceBehavioral NeuroscienceBrain Function	2006	228
Neurotic illness and its response to anxiolytic and antidepressant treatment Eve C. Johnstone, D. G. Cunningham Owens, Chris Frith, Psychological Medicine	1980	216
Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor Barry S. Orlek, Frank E. Blaney, Frank Brown, Journal of Medicinal Chemistry	1991	204
5-Chloro-<i>N</i>-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT<sub>6</sub> Receptor Antagonist Steven M. Bromidge, Anthony M. Brown, Stephen E. Clarke, Journal of Medicinal Chemistry Drug TargetAltmetric Attention Score4-Methoxy-3-piperazin-1-yl- PhenylPharmacotherapySystem Pharmacology	1999	170
Characterization of SB‐271046: A potent, selective and orally active 5‐HT<sub>6</sub> receptor antagonist Carol Routledge, Steven M. Bromidge, Stephen F. Moss, British Journal of Pharmacology Receptors Sb-271046PharmacotherapyExperimental PharmacologyActive 5‐HtRat Mest Test	2000	136

Page 1